Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Durable responses with fianlimab plus cemiplimab in advanced melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the long-term data from a Phase I study (NCT03005782) of fianlimab and cemiplimab, noting that patients with a partial response or better tend to have a favorable outcome. If progression does not occur within a certain timeframe, approximately three years, the likelihood of never progressing is 95% or higher, allowing for a positive prognosis for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So the long-term data suggests that if you have a partial response or better, that you do well. The data show that if you do not progress by a certain time, and we’re seeing it’s around three years, that you really have a 95% or more chance of never progressing. So it’s a good timeline to be able to tell patients that this is what we’re seeing, a flattening of the survival curve, a plateau, and this plateau remains with this combination similar to other checkpoint combinations...

So the long-term data suggests that if you have a partial response or better, that you do well. The data show that if you do not progress by a certain time, and we’re seeing it’s around three years, that you really have a 95% or more chance of never progressing. So it’s a good timeline to be able to tell patients that this is what we’re seeing, a flattening of the survival curve, a plateau, and this plateau remains with this combination similar to other checkpoint combinations.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.